Welcome to our dedicated page for CALCIMEDICA SEC filings (Ticker: CALC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CalciMedica's SEC filings reveal the financial trajectory and operational decisions of a clinical-stage biopharmaceutical company advancing calcium channel inhibitors through human trials. The company's 10-Q quarterly reports detail cash burn rates, research and development expenditures, and runway projections that determine how long current capital can sustain operations before additional financing becomes necessary.
Form 4 filings track insider transactions, showing when executives and directors buy or sell shares. These transactions sometimes precede material announcements about clinical trial results or financing activities. CalciMedica's 8-K filings disclose material events including clinical trial updates, partnership agreements, and changes in capital structure. The prospectus supplements (424B5 forms) provide detailed terms of securities offerings, including share prices, dilution effects, and use of proceeds for specific research programs.
The company's annual 10-K filings offer comprehensive discussions of clinical trial designs, competitive landscape analysis, and risk factors specific to CRAC channel drug development. These documents explain the regulatory pathway for acute pancreatitis therapies and identify which biomarkers the company measures to demonstrate drug efficacy. Proxy statements reveal executive compensation structures and how management incentives align with clinical milestones.
Our AI-powered summaries extract key financial metrics from dense accounting disclosures, highlight changes in trial timelines buried in MD&A sections, and identify when insider buying patterns shift. No need to parse through 100+ pages of technical documentation to understand whether CalciMedica's cash position supports its stated development plans or when the next catalyst event might occur.
CalciMedica, Inc. (CALC) – Form 4 filed 10 Jul 2025
Chief Business Officer, Director and 10% owner Eric W. Roberts reported an open-market purchase of 5,000 common shares on 09 Jul 2025 at $1.6047 per share. After the transaction, he beneficially owns roughly 1,002,410 CALC shares distributed across direct holdings (164,706 shares), several Roth/Traditional IRAs and three Valence Investments SPVs, the largest of which holds 356,989 shares. No derivative securities were transacted in this filing.
The acquisition marginally increases Roberts’ stake by about 0.5% and may signal incremental confidence, though the dollar value is modest relative to his existing position.
On 07/01/2025, CalciMedica, Inc. (ticker CALC) filed a Form 4 disclosing that its Chief Scientific Officer, Kenneth A. Stauderman, executed a single open-market purchase marked with transaction code “P.” The transaction, carried out through his spouse’s account, involved 1,000 shares of CalciMedica common stock at a price of $1.85 per share, for an aggregate cost of roughly $1,850. Following the purchase, Stauderman reports indirect beneficial ownership of the 1,000 newly acquired shares and direct ownership of 11,944 shares. No derivative transactions were reported, and the filing is made solely by one reporting person. The form does not indicate use of a Rule 10b5-1 plan.
Eric W. Roberts, Chief Business Officer, Director, and 10% Owner of CalciMedica (CALC), reported significant insider trading activity on June 26, 2025. Roberts purchased 4,500 shares of common stock at a weighted average price of $1.4406 per share through his Roth IRA account.
Following this transaction, Roberts' total beneficial ownership includes:
- 164,706 shares held directly
- 832,704 shares held indirectly through various entities including:
- Multiple Roth IRA accounts totaling 93,378 shares
- Valence Investments SPV entities holding 739,326 shares across three vehicles
The transaction demonstrates continued insider confidence in CalciMedica, with Roberts maintaining substantial holdings both directly and through investment vehicles. The purchase price range was between $1.43 and $1.4499 per share.
CalciMedica (symbol: CALC) has filed a Post-Effective Amendment No. 1 to its Form S-8 Registration Statement (No. 333-288287) on June 27, 2025. The amendment's sole purpose is to include Exhibit 23.3 - the Consent of Ernst & Young LLP as Independent Registered Public Accounting Firm - which was inadvertently omitted in the original filing.
The filing relates to the company's 2023 Equity Incentive Plan and 2023 Employee Stock Purchase Plan. CalciMedica is identified as a:
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
The company is led by A. Rachel Leheny, Ph.D. as CEO and Principal Executive Officer, with Stephen Bardin serving as CFO. The board is chaired by Robert N. Wilson. The company is headquartered in La Jolla, California, and operates under Delaware jurisdiction.
CalciMedica (NASDAQ: CALC) filed an 8-K summarizing the 2025 Annual Meeting held on 24 Jun 2025.
- Equity Incentive Plan amended: share reserve increased by 600,000 shares (≈4.3 % of the 13.97 M shares outstanding).
- Three Class II directors—Rachel Leheny, Eric Roberts, Frederic Guerard—re-elected for terms ending 2028.
- Baker Tilly US ratified as independent auditor for FY 2025.
The amendment enhances retention tools but introduces incremental dilution; no additional financial data or strategic shifts were disclosed.
CalciMedica Chief Medical Officer Sudarshan Hebbar received a stock option grant for 83,300 shares of common stock on June 24, 2025. The options were granted with an exercise price of $1.53 per share and are immediately exercisable with an expiration date of April 22, 2035.
Key details of the transaction:
- The option grant was initially approved by the Board on April 23, 2025, contingent on stockholder approval
- Stockholders approved the amended 2023 Equity Incentive Plan on June 24, 2025, finalizing the grant
- Options represent direct ownership and were granted under the company's Amended 2023 Equity Incentive Plan
- The filing was signed by John Dunn as attorney-in-fact on June 26, 2025
CalciMedica, Inc. (CALC) – Form 4 insider transaction by CFO Stephen Bardin
On 26 June 2025, Chief Financial Officer Stephen Bardin executed two reportable transactions:
- Open-market purchase: 2,000 shares of CALC common stock at a weighted-average price of $1.5025 (price range $1.45-$1.54). The shares are held indirectly by The Bardin Family Trust dated 4 June 2024.
- Employee stock option grant: 20,000 options with an exercise price of $1.53 per share, immediately exercisable and expiring 22 April 2035. The grant was approved by the Board on 23 April 2025 and became effective upon shareholder approval of the amended 2023 Equity Incentive Plan on 24 June 2025.
Post-transaction ownership
- Indirect: 3,000 shares (Bardin Family Trust)
- Direct: 40,000 shares
- Derivative: 20,000 stock options
The filing also corrects a prior Form 4 (3 June 2025) that had misclassified 1,000 trust-held shares as directly owned. No other financial metrics or operational updates were included.
FAQ
What is the current stock price of CALCIMEDICA (CALC)?
What is the market cap of CALCIMEDICA (CALC)?
